Across the pharmaceutical industry, there is a broad need for improved efficiency to increase the translation of science from bench to clinic. One area that is ripe for improvement is the predictiveness of preclinical models. View this session to hear a panel of experts discuss how complex in vitro models are helping to improve efficacy and ADME-Tox evaluation of drug candidates to bridge the translational gap.
Speakers:
Jason Ekert, PhD
Head of US Discovery Translational Technology
UCB
Kimberly Homan, PhD
Director, Complex in vitro Systems
Genentech